AI-supported screening and treatment selection for cervical cancer in low-income countries
Official title: A Novel, One Stop, Affordable, Point of Care and Artificial Intelligence Supported System of Screening, Triage and Treatment Selection for Cervical Cancer and Precancer in the Low-to-middle Income Countries
Run by International Agency for Research on Cancer · NCT06042543 · Data updated 2026-11-12
This study is testing a new AI system that uses urine samples and cervical images to help find cervical cancer in women aged 25 to 49 in low-income countries who haven't been screened recently.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 25 Years to 49 Years |
| Sex | Women only |
| Enrollment | 3200 (estimated) |
| Sponsor | International Agency for Research on Cancer Academic / other |
| Locations | 2 sites (Cincinnati, Ohio and 1 other locations) |
| Status | Recruiting |
| Started | December 9, 2023 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | June 1, 2026 |
| Trial ID | NCT06042543 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are women aged 25 to 49 who have not undergone cervical screening in the past three years.
✕Probably not a fit
Patients who are actively menstruating, pregnant, or have previously been treated for cervical precancer or cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to develop and validate a novel artificial intelligence system for cervical cancer screening and treatment decision-making. The AI will analyze infrared spectroscopic signals from urine samples to detect high-risk human papillomavirus (hr-HPV) and interpret cervical images to identify high-grade precancers and cancers. By screening 3200 women aged 25 to 49 who have not been screened in the last three years, the study seeks to improve cervical cancer outcomes in low- and middle-income countries. The approach combines innovative technology with a focus on accessibility and affordability.
Why it matters
Potential benefit: If successful, this study could significantly enhance early detection and treatment of cervical cancer, potentially saving lives in underserved populations.
How similar studies have gone: Other studies have shown promise in using AI for cancer detection, but this specific approach combining urine spectroscopy and AI for cervical cancer screening is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * No cervical screening during the previous 3 years * Between the ages of 25 and 49 years * Understands and signs a written informed consent form Exclusion Criteria: * Refusal to take part for any reason * Actively menstruating or pregnant * Treated earlier for cervical precancer or cancer
Where it's running
-
University of Cincinnati
Cincinnati, Ohio, United States Recruiting -
University of Zimbabwe
Harare, Zimbabwe Recruiting
Study contacts
- Principal investigator: Partha Basu, MD — International Agency For Research On Cancer (IARC)
- Study coordinator: Partha Basu, MD
- Email: basup@iarc.who.int
- Phone: +33764485370
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cervical screening and care options for women living with HIV who test positive for high-risk HPV
This study tests different ways to screen and manage high-risk HPV in women with HIV to see what might work best for them.
-
Hydrogel spacer to protect the rectum during cervical cancer radiotherapy
This study tests whether placing an absorbable hydrogel spacer between the cervix/vagina and rectum before definitive radiotherapy can reduce rectal radiation exposure for women with cervical cancer.
-
How cinema sessions during chemotherapy might help cervical cancer patients
We’re testing if watching films during chemotherapy helps cervical cancer patients feel less anxious and improve quality of life.
-
One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy
This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
Stellate ganglion block and dexmedetomidine for better sleep after gynecologic laparoscopy
The study tests whether giving a preoperative stellate ganglion block plus intraoperative dexmedetomidine improves sleep after laparoscopic gynecologic surgery in women.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.